ORIC — Oric Pharmaceuticals, Inc.

—
Nasdaq · Health Care · Pharmaceuticals · CIK 1796280 ·
Last close
$8.00
Market Cap
$829.22M
52W High
$14.68
52W Low
$7.23
ADV30
1,792,762
Next earnings
2026-11-16

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGross profitOp incomeNet incomeAssetsCashLiabilities
Sep 2026 0 — -51,551,000 -48,076,000 366,886,000 33,846,000 27,383,000
Jun 2026 0 — -45,296,000 -41,492,000 404,685,000 37,483,000 23,429,000
Mar 2026 0 — -39,619,000 -35,767,000 436,762,000 56,396,000 21,205,000
Dec 2025 0 — -34,551,000 -30,505,000 408,890,000 45,669,000 24,528,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-111,638,000
Investing CF
$-99,662,000
Financing CF
$172,919,000
CapEx
$-620,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-1.35
As of
2026-11-08

Balance + Analyst (yfinance extras)

Retained Earnings
$-769,501,000
Inventory
—
Receivables
—
ST Investments
$227,278,000
EBIT TTM
$-156,137,000
Pretax Income TTM
$-140,351,000
Interest Exp TTM
—
Analysts
14

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOp incomeNet incomeAssetsLiabilitiesEquityOp cash flow
Dec 2025 0 -143,004,000 -129,468,000 408,890,000 24,528,000 384,362,000 -110,970,000
Dec 2024 0 -142,895,000 -127,847,000 274,142,000 31,020,000 243,122,000 -112,662,000
Dec 2023 0 -110,780,000 -100,697,000 252,007,000 27,919,000 224,088,000 -85,688,000
Dec 2022 0 -86,767,000 -89,122,000 247,178,000 24,827,000 222,351,000 -75,143,000

TTM Snapshot

Revenues TTM
$0
NetIncome TTM
$-140,351,000
OpCashFlow TTM
—
Assets (Latest)
$404,685,000
Forward EPS
$-1.61

Max Pain — expiry 2027-01-15

max pain strike: $10.00 · spot: $7.65 · call oi: 3,044 · put oi: 2,361

Peers — same industry

TickerNameMarket CapLastDaily %
SNDX Syndax Pharmaceuticals Inc $828.26M $9.20 —
CTY CITY THERAPEUTICS, INC. $846.44M $17.50 —
RIGL RIGEL PHARMACEUTICALS INC $808.18M $42.92 —
IRWD IRONWOOD PHARMACEUTICALS INC $806.23M $4.87 —
PHAR Pharming Group N.V. $853.58M $12.06 —

News headlines (Yahoo Finance, 1h cache)

ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
2026-11-06 21:30 · Yahoo
ORIC® Pharmaceuticals to Participate in Upcoming Investor Conferences
2026-11-03 21:01 · Yahoo
ORIC Pharmaceuticals (ORIC) Stock Sees Modest Fair Value Lift On Trial Catalyst Optimism
2026-10-27 10:12 · Yahoo
ORIC Pharmaceuticals Sinks 22% as J&J Presents Rival Prostate Cancer Data
2026-10-26 16:39 · Yahoo
Oric Pharmaceuticals’ Enozertinib Shows 88% Response Rate in EGFR Lung Cancer Study
2026-10-23 17:04 · Yahoo
ORIC® Pharmaceuticals Presents Preclinical and Translational Data to Support the Potential of Rinzimetostat to Enhance Sensitivity to Androgen Receptor Inhibition in Prostate Cancer at ESMO Congress 2
2026-10-23 07:15 · Yahoo
ORIC® Pharmaceuticals Presents Potential Best-in-Class Data for Enozertinib in 1L NSCLC Patients with EGFR Atypical Mutations at ESMO Congress 2026 and Plans to Advance Enozertinib into a Global Phase
2026-10-23 07:15 · Yahoo
ORIC Stock In Focus As New Lung Cancer Trial Data Heads To ESMO 2026
2026-10-21 04:26 · Yahoo
ORIC® Pharmaceuticals to Host Conference Call & Webcast to Review Enozertinib Data Being Presented at ESMO Congress 2026
2026-10-19 12:00 · Yahoo
Does ORIC (ORIC) Using Off‑Balance‑Sheet Funding for ORIC‑259 Redefine Its R&D Risk Strategy?
2026-10-08 17:12 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.